Mammoth Biosciences Secures Exclusive License to Commercialize Novel CRISPR Protein

Mammoth Biosciences, the company behind the world's first CRISPR-based disease detection platform, announces the exclusive licensing of a new CRISPR protein, Cas14, from UC Berkeley, for use in all fields. Two of Mammoth Biosciences' co-founders, Lucas Harrington and CRISPR pioneer Jennifer Doudna, were part of the team that discovered the protein.  Each CRISPR Cas protein offers a particular application by virtue of its speed, precision, and cost. Cas14, as the smallest protein discover…

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=237431


Source: webwire
Mammoth Biosciences Secures Exclusive License to Commercialize Novel CRISPR Protein



Leave a Reply